Meeting News

Guest Commentary: DECLARE-TIMI 58 trial validates CV benefits of SGLT2 inhibitors in type 2 diabetes

January 4, 2019
Results from the DECLARE-TIMI 58 trial, presented during a late-breaking session at the 2018 American Heart Association Scientific Sessions, add to
Meeting News

Cardiologists should recognize CV benefit, increase prescribing of SGLT2 inhibitors, GLP-1 receptor agonists

January 1, 2019
CHICAGO —A speaker at the American Heart Association Scientific Sessions called on cardiologists to become more involved in the use of SGLT2…
Meeting News

Speaker highlights concordance of studies, BP guidelines in diabetes

December 20, 2018
CHICAGO — Data from multiple trials show a similar effect of systolic BP lowering on CV outcomes between patients with diabetes and those…
Meeting News

Data support intensive lipid-lowering therapy in diabetes

December 18, 2018
CHICAGO — Although recent trials indicate intensive lipid-lowering therapy is advantageous for patients with diabetes, specific LDL targets…
Meeting News

Q&A: A closer look at class effects of SGLT2 inhibitors on CV outcomes in diabetes

December 17, 2018
An expert consensus decision pathway recently published by the American College of Cardiology highlights studies that show SGLT2 inhibitors…
Meeting News

Liraglutide, semaglutide beneficial in diabetes regardless of baseline BMI, BP

December 14, 2018
CHICAGO — Two post-hoc analyses of data from the LEADER and SUSTAIN 6 trials presented at the American Heart Association Scientific Sessions…
Meeting News

Emphasize patient adherence, dietary patterns in recommending diets for patients with diabetes

December 13, 2018
CHICAGO — While diets that emphasize increasing or decreasing a single nutrient class, such as high-carbohydrate or low-fat diets, are trending…
Meeting News

Aggressive intervention improves glycemic control among non-adherent patients with diabetes

December 6, 2018
CHICAGO —Aggressive intervention with insulin in patients with type 2 diabetes who were at risk for being non-adherent resulted in improved…
Meeting News

ACCORD: Premixed insulin use, renal events predict CV outcomes in patients with diabetes

December 4, 2018
CHICAGO — A new analysis of data from the ACCORD trial showed that use of premixed insulin and renal microvascular events predicted the…
Meeting News

Dapagliflozin confers more favorable cardiometabolic outcomes vs. vildagliptin

November 29, 2018
CHICAGO — The SGLT2 inhibitor dapagliflozin was more beneficial than the DPP4 inhibitor vildagliptin in reducing BMI and systolic BP and…